Diabetes Drug Study Explores Cardiovascular Risks for Patients with Kidney Disease
Vanderbilt University Medical CenterAmong the 30 million U.S. adults with Type 2 diabetes, 20% have impaired kidney function. In patients like this, metformin, the recommended first-line drug therapy for Type 2 diabetes, is associated in the new study with 20 percent decreased risk of major adverse cardiovascular events when compared to a class of common diabetes drugs called sulfonylureas.